Cancer Genetics to Sponsor and Host Roundtable at BioNJ Diagnostics & Personalized Medicine Innovati

Cancer Genetics to Sponsor and Host Roundtable at BioNJ Diagnostics & Personalized Medicine Innovation Summit

RUTHERFORD, N.J.--(BUSINESS WIRE)-- Cancer Genetics, Inc. (OTCQB: CGIX) ("CGI" or the "Company"), a leader in oncology-focused personalized medicine, will sponsor and host a roundtable discussion at the second annual BioNJ Diagnostics & Personalized Medicine Innovation Summit on Thursday, June 6, 2013 at Sanofi's U.S. headquarters in Bridgewater, NJ.

The BioNJ Diagnostics & Personalized Medicine Innovation Summit will bring together leaders from major global biotechnology and pharmaceutical companies, diagnostics companies, and emerging "innovator" companies to discuss the latest trends, developments and challenges in the evolution and adoption of personalized medicine. The all-day event will include company presentations, networking opportunities, and moderated panel discussions focused on research and commercialization challenges in diagnostics and personalized medicine.

Panna Sharma, CEO and President of CGI, will moderate a morning roundtable discussion that will offer a cross-industry perspective from thought leaders and operators in the frontline of driving personalized medicine. The panel will discuss trends and strategies that are emerging among leading companies in personalized medicine. Panelists include:

  • G. Steven Burrill, CEO, Burrill & Company
  • Sam Chawla, Managing Director Global Head of Diagnostics and Tools, UBS Investment Bank
  • Kevin DeGeeter, Managing Director Personalized Medicine Research Analyst, Ladenburg Thalmann & Co.
  • Sung Ji Nam, Life Science Tools & Diagnostics Analyst, Cantor Fitzgerald
  • Frank Prendergast, M.D., Ph.D., Professor of Biochemistry & Molecular Biology and Professor of Molecular Pharmacology & Experimental Therapeutics, The Mayo Clinic

To learn more about the BioNJ Diagnostics & Personalized Medicine Innovation Summit, visit

About Cancer Genetics, Inc.

Cancer Genetics, Inc. (CGI) is an emerging leader in DNA-based cancer diagnostics and services some of the most prestigious medical institutions in the world. Our tests target cancers that are difficult to diagnose and predict treatment outcomes. These cancers include hematological, urogenital and HPV-associated cancers. We also provide a comprehensive range of non-proprietary oncology-focused tests and laboratory services.

CGI's cutting-edge proprietary tests and state-of-the-art reference laboratory provide critical genomic information to healthcare professionals as well as biopharma and biotech. Our state-of-the-art reference lab is focused entirely on maintaining clinical excellence and is both CLIA certified and CAP accredited and has licensure from several states including New York State.

Founded in 1999 by world-renowned cytogeneticist Dr. R.S.K. Chaganti, the Company has been built on a foundation of world-class scientific knowledge and IP in solid and blood-borne cancers, and has established strong research collaborations with major cancer centers such as Memorial Sloan-Kettering, The Cleveland Clinic and the National Cancer Institute. For further information, please see

Investor Relations
RedChip Companies, Inc.
Jon Cunningham, 800-733-2447, ext. 107

KEYWORDS:   United States  North America  New Jersey


The article Cancer Genetics to Sponsor and Host Roundtable at BioNJ Diagnostics & Personalized Medicine Innovation Summit originally appeared on

Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story